Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook
Zymeworks ((ZYME)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zymeworks’ latest earnings call struck an upbeat tone, with management emphasizing strong clinical validation for zanidatumab, accelerating revenue, and a creative financing deal that avoids equity dilution. While executives acknowledged dependence on future milestones and some clinical uncertainty, they argued that recent data and partnerships meaningfully de-risk the story for long-term investors.
Phase III HORIZON-GEA-01 Underscores Zanidatumab’s Potential
Phase III HORIZON-GEA-01 delivered standout results in first-line HER2-positive gastric and gastroesophageal adenocarcinoma, with median progression-free survival above one year and median overall survival above two years. The benefit extended across key subgroups regardless of PD-L1 status, and a further interim overall survival analysis is slated for mid-2026, with partner Jazz targeting a 2026 supplemental filing.
New Approvals Open Additional Commercial Doors
Zanidatumab has already begun to translate its clinical profile into approvals as a second-line monotherapy for biliary tract cancer in Canada and the U.K., laying the groundwork for broader commercial reach. Zymeworks stands to collect up to about $1.5 billion in remaining regulatory and commercial milestones across indications under existing collaboration deals, including sizeable payments tied to gastric cancer.
Revenue Ramps While Losses Narrow
Total revenue climbed to $106.0 million in 2025 from $76.3 million a year earlier, a roughly 39% jump driven largely by clinical and regulatory milestones and partner option exercises. The company’s net loss shrank to $81.1 million from $122.7 million, signaling improving operating leverage even as investment in key programs continued.
Royalty-Backed Note Delivers Nondilutive Capital
Zymeworks secured $250 million in nondilutive funding through a nonrecourse royalty-backed note with Royalty Pharma, designed to extend runway without issuing new shares. Only 30% of zanidatumab royalties are pledged until the note is repaid, with Zymeworks retaining 70% of royalties and all regulatory and commercial milestones throughout the life of the deal.
Pipeline Beyond Zanidatumab Continues to Advance
The company highlighted meaningful progress across its antibody-drug conjugate and T-cell engager pipeline, with GPC3-targeting ADC ZW251 now dosing patients in a multi-region Phase I trial at an initial 3.2 mg/kg. Additional programs, including ZW191 and multispecific candidates ZW209 and ZW1528, are moving toward key data updates and planned regulatory submissions in 2026, while a partnered asset, pasritamig, is showing encouraging early signals.
Cost Controls Tighten as Strategy Shifts to Efficient Growth
Management underscored its focus on discipline, noting GAAP operating expenses declined to $198.5 million from $213.4 million, a roughly 7% reduction. The company laid out an adjusted operating expense framework of about $300 million over 2026–2028, targeting approximately 20% lower adjusted gross operating expenses in 2026 versus 2025, excluding any acquisition-related costs.
Buybacks Signal Confidence but Raise Trade-Off Questions
Zymeworks continues to view its share repurchase program as a tool to return capital when it sees a disconnect between market value and intrinsic prospects, having deployed roughly $62.5 million of its $125 million authorization. While this underscores management’s confidence, it also reduces immediate balance sheet flexibility if expected milestones or royalty streams are delayed.
Runway Extended but Tied to Milestone Execution
The company ended 2025 with $270.6 million in cash, cash equivalents, and marketable securities, down from $324.2 million a year earlier after funding operations, investments, and repurchases. Management believes existing resources, anticipated gastric cancer milestones, and proceeds from the Royalty Pharma note can fund operations beyond 2028, though this outlook depends on achieving key regulatory triggers.
Cash Burn and High Operating Spend Remain Watch Points
Despite improvements, cash resources declined by about $53.6 million, or 16.5%, over the year, reflecting continued investment and capital returns. Operating expenses remain high at $198.5 million, with research and development still a major cost driver as noncash compensation, consulting, and infrastructure spend offset savings from discontinued programs.
Clinical and Royalty Structures Introduce Residual Risk
Management acknowledged that the initial interim overall survival analysis for zanidatumab in gastric cancer narrowly missed statistical significance, leaving investors awaiting a critical mid-2026 readout and later timelines for breast cancer data, potentially stretching to 2027–2028. In addition, 30% of future zanidatumab royalties are temporarily pledged to the note, modestly reducing near-term royalty cash flow and amplifying the importance of successful milestones.
Forward Guidance Points to Key 2026–2028 Catalysts
Looking ahead, Jazz intends to file for U.S. approval of zanidatumab in first-line gastric cancer in 2026, aiming for a potential launch in the second half of that year, alongside the next overall survival analysis from HORIZON-GEA-01. Zymeworks expects its extended cash runway, lower 2026 operating expenses, and a slate of upcoming data milestones, including EMPOWUR-303 breast cancer results by late 2027 or early 2028, to support a multiyear cycle of potential value creation.
Zymeworks’ call painted the picture of a company transitioning from pure development story to one with increasingly visible commercial and financial contours, anchored by zanidatumab’s promising Phase III profile. For investors, the combination of rising revenues, nondilutive capital, and a broad partnering base offers upside, but the path still hinges on pivotal regulatory decisions, timely milestones, and disciplined capital deployment.
